why choose us

First received: July 27, 2022

Clinical Trial: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

Study Status: Completed

Recruit Status: RECRUITING

Condition: Idiopathic Pulmonary Fibrosis

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as Mono- or add-on Therapy, in Patients With Idiopathic Pulmonary

Brief Summary: This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).

Read more